Wealth Advisors Northwest LLC Acquires Shares of 739 Amgen Inc. (NASDAQ:AMGN)

Wealth Advisors Northwest LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 739 shares of the medical research company’s stock, valued at approximately $230,000.

Several other institutional investors have also modified their holdings of the stock. Stanley Laman Group Ltd. grew its position in shares of Amgen by 32.8% during the first quarter. Stanley Laman Group Ltd. now owns 13,215 shares of the medical research company’s stock worth $4,117,000 after acquiring an additional 3,262 shares during the last quarter. Everhart Financial Group Inc. raised its position in Amgen by 91.8% in the 1st quarter. Everhart Financial Group Inc. now owns 3,750 shares of the medical research company’s stock valued at $1,168,000 after purchasing an additional 1,795 shares during the last quarter. Smithbridge Asset Management Inc. DE purchased a new position in Amgen during the 1st quarter worth $250,000. Relyea Zuckerberg Hanson LLC grew its position in Amgen by 6.5% during the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 1,719 shares of the medical research company’s stock worth $536,000 after purchasing an additional 105 shares during the last quarter. Finally, Verity & Verity LLC increased its stake in Amgen by 4.0% in the first quarter. Verity & Verity LLC now owns 96,157 shares of the medical research company’s stock valued at $29,958,000 after purchasing an additional 3,667 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Mizuho boosted their price target on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday, May 7th. UBS Group reissued a “neutral” rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Guggenheim started coverage on Amgen in a report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price target for the company. Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Finally, Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $309.22.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $297.29 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company’s 50-day moving average price is $281.03 and its 200 day moving average price is $285.48. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock has a market cap of $159.85 billion, a price-to-earnings ratio of 39.38, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the business earned $3.96 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. As a group, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.